Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to 0.
While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, ...
STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...
Overview of study design and analytical flow for identifying metabolic features associated with anti-VEGF therapy on macular edema (ME) patients (created with BioRender.com). anti-VEGF, anti-vascular ...
Branch retinal vein occlusions (BRVOs) typically occur at arteriovenous crossings, where the artery and vein share a common membranous sheath. Degenerative changes can cause hardening of the retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results